Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

40 patients--5 to 50 years of age--voiding eggs of Schistosoma haematobium in their urine--underwent treatment with Metrifonate at the OPD of Bong Mine Hospital, Liberia. The patients received 10 mg/kg body weight 3 times at a fortnight's interval. The drug was swallowed under medical supervision. 27 patients no longer passed eggs after the 1. dose of Metrifonate, 37 no longer voided eggs after the 2. administration. 1 patient did not show up for control after the 3. dose. Theoretically he may not be healed. 1 other patient who came for control after 12 months had been exposed to reinfection and again voided eggs in her urine. She had been negative after the 2. treatment. Reinfection may have happened. Patients could be controlled over a period of 6-14 months. Thus, Metrifonate seems to be an effective drug in the treatment of urinary schistosomiasis. Side-effects (nausea, abdominal pains, and--very rare--vomiting) were mild and disappeared spontaneously within less than 24 hours after medication. Patients did not have to interrupt school, daily activities, and treatment. Statistically, Metrifonate did not show any influence on transaminase SGOT, SGPT, and LDH during and after the course of treatment. The same evaluation applies to eosinophilia. There is no increase or decrease of this particular type of cell during and after treatment 7 patients showed alterations of their ECG curves. There were changes of the T-wave in V1-4. In adults traces were normal again several months after completion of treatment. It seems to be difficult to interpret ECGs in West African youngsters. X-ray photos of the lungs never revealed any pathological findings which could be connected to the course of treatment. Metrifonate seems to be a valuable drug in treatment of Schistosoma haematobium-infection. The drug is well tolerated if the treatment scheme--mentioned above--is used.
 ...
PMID:[Treatment of schistosomiasis haematobium with metritionate in OPD-patients (author's transl)]. 101 47

For studying the side effects of praziquantel in children with active intestinal bilharziasis 6 groups of children were followed: group P-1 (active intestinal bilharziasis +/- hepatosplenomegaly). They were treated with praziquantel (40 mg/Kg b.w. orally every 6 months). group P-2 (children with active mansoniasis +/- hepatosplenomegaly. They were treated with an initial full dose of praziquantel (40 mg/kg) to be followed by suppressive dose (20 mg/kg) at 3-months intervals, group P-3 (school children with active mansoniasis +/- hepatosplenomegaly). Initial loading praziquantel dose was followed by suppressive dose at monthly intervals, group N-1 (non-bilharzial children given an oral monthly praziquantel prophylactic dose of 20 mg/kg, group N-2 (non-bilharzial children given an oral 3-monthly praziquantel prophylactic dose of 20 mg/kg), group N-3 (non-bilharzial school children given an oral placebo in the form of vitamin B complex tablets at 3-monthly intervals. Surveillance for praziquantel adverse reactions for all these groups was done. It revealed that the adverse reactions were nausea, vomiting, abdominal colic, diarrhea, dizziness, headache and pyrexia. These were noticed more after full therapeutic praziquantel dose than half doses (subcurative or prophylactic) & among bilharzial children than non-bilharzial cases. As regards school children with active urinary hematobiasis 3 groups were followed: Group 1 (school children with active urinary hematobiasis treated with praziquantel orally 40 mg/kg b.w. every 6 months). Group 2 (non-bilharzial school children given oral monthly prophylactic dose of 20 mg/kg b.w. praziquantel). Group 3 (non-bilharzial school children given oral placebo in the form of two vitamin B-complex tablets monthly).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Side effects of praziquantel in bilharzial children on a field level. 212 46

Eighty-four cases of schistosomiasis mekongi among Cambodian refugees in holding centres in Thailand received praziquantel at 30 mg/kg body-weight orally twice in one day. Those treated were admitted to hospital in order to observe side effects for 24 hours. Assessment of the efficacy of praziquantel was based on cure rates. Side effects observed consisted primarily of abdominal pain, anorexia, nausea, emesis and headache. These were generally mild and transient. Physical signs revealed mild hepatomegaly and splenomegaly. The cure rate obtained one month after treatment was 97.5% and by 2 to 12 months after treatment reached 100%.
 ...
PMID:Treatment of Schistosoma mekongi with praziquantel in Cambodian refugees in holding centres in Prachinburi Province, Thailand. 648 54

The authors study the results of a treatment of 700 cases of bilharziasis seen in Paris and in two foci in Togo, by oxamniquine, oltipraz or praziquantel. The three drugs are well tolerated; only a few mild side-effects were reported such as discomfort, nausea, headaches (two cases of acrodynia with oltipraz ). The three drugs are very efficacious in the case of schistosomiasis mansoni (85,5% success rate with oxamniquine, 92,9% with praziquantel, from 76,5 to 92% with oltipraz depending on the different strains) at day 180. As far as schistosomiasis haematobium is concerned, oltipraz and praziquantel have a 87,5% success rate with oltipraz and 80% with praziquantel; however, in the case of oltipraz , it is necessary to increase the dose. The action of praziquantel seems to be slower on Schistosoma haematobium than on S. mansoni. By the study of the evolution of antibodies, the fast action of praziquantel was noticed, explaining the peak of serological titers and of eosinophilia as early as day 10 after treatment; in the case of oltipraz , the apparition of this peak is only recorded at the 30th day. The slower effect of oltipraz on worms implicates not to judge its efficacy by too early controls.
 ...
PMID:[Treatment of 700 cases of bilharziasis with the new drugs oxamniquine, oltipraz, praziquantel]. 667 43

Fourteen patients with active schistosomiasis mansoni in spite of previous treatment with oxamniquine and/or hycanthone were treated with praziquantel, single oral dose of 45 to 50 mg/kg body-weight. All underwent clinical, laboratory and electrocardiographic examination before and after treatment. Untoward effects (dizziness, drowziness, nausea and abdominal pain) were observed in ten. Laboratory findings disclosed no significant alteration and the electrocardiograms showed no abnormalities. Monthly follow-up examinations of 13 patients for six consecutive months showed parasitological cure in all. Before praziquantel treatment strains of Schistosoma mansoni were isolated from two patients, one treated three times with oxamniquine and the other with hycanthone once and oxamniquine twice. Progenies of these strains were maintained in Biomphalaria glabrata and mice. Groups of these infected mice were then treated with oxamniquine, hycanthone, niridazole and praziquantel and results compared with the BH strain maintained in our laboratory for many years. Schistosomicidal activity was assessed by the localization of worms in the portal vein system and oogram changes. Progenies from the strains isolated in this study were resistant to oxamniquine and hycanthone but sensitive to niridazole and praziquantel. The BH strain was sensitive to all four drugs. The serial runs of S. mansoni strains through intermediate and definitive hosts have not influenced their reactions to these schistosomicides.
 ...
PMID:Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents. 717 19

2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino [2,1-a]isoquinolin-4-one (praziquantel, EMBAY 8440, Biltricide) was administered to 78 patients aged from 6 to 18 years. They were divided into 3 groups, receiving single doses of 30 mg and 40 mg/kg b.w. and 2 doses of 20 mg/kg b.w. (at an interval of 6 h), respectively. Tolerance examinations showed that 65% of the patients treated did not complain of any side effects. The remaining patients mentioned abdominal pain, headache and/or nausea. All these symptoms disappeared within a few hours without special treatment. Compared with pretreatment results, clinical examinations after treatment did not reveal any significant changes of haematocrit, haemoglobin, transaminases and bilirubin. Follow-up urine examinations were carried out 6 months after treatment in 71 children, of whom 68 were found to be no longer excreting viable eggs of Schistosoma. This corresponds to a parasitological cure rate of 95.8%. In the three patients who were not cured the number of eggs excreted was reduced by 89.2%. No statistically significant difference in efficacy was recorded between the three doses administered. Praziquantel appears to be an effective, well tolerated and easily administrable schistosomicide and thus a favourable contribution to the control of urinary schistosomiasis.
 ...
PMID:[Trial of praziquantel in the treatment of urinary schistosomiasis in Senegal]. 719 48

The stools of 35 patients with S. intercalatum bilharziasis are examined 48 hours, 45 days and 6 months after treatment, using praziquantel, a new trematodicide drug, in an individual single dose of 40 mg/kg body weight. The number of eggs per gram of faeces is not significantly reduced 2 days after treatment. After 45 days however eggs are only to be found in the stool of one patient among the 25 treated persons who were seen for control. Six months later 23 persons were examined again and 3 stools specimens were found positive, this being possibly due to reinfection. The drug has been well tolerated, except for minor side effects such as headache, nausea and abdominal discomfort.
 ...
PMID:[Sensitivity of S. intercalatum to praziquantel (author's transl)]. 733 24

After returning from Africa, a 54-year-old man began to have episodes of headache and nausea, then a cerebral convulsion. Clinical and laboratory findings and response to chemotherapy indicated the diagnosis of cerebral schistosomiasis. Three lesions were seen on CT and MR studies: two appeared to be subacute intracerebral hematomas, one in the right parietal lobe and one in the frontal lobe; the third lesion, in the cortex of the left occipital lobe, appeared to be a cyst. These lesions could represent small granulomatous tissue reactions with secondary hemorrhages.
 ...
PMID:Cerebral schistosomiasis: MR and CT appearance. 888 65

A double-blind placebo-controlled study of the concurrent administration of albendazole and praziquantel was conducted in>1500 children with high prevalences of geohelminths and schistosomiasis. The study sites were in China and the Philippines, including 2 strains of Schistosoma japonicum, and 2 different regions of Kenya, 1 each with endemic Schistosoma mansoni or Schistosoma haematobium. Neither medication affected the cure rate of the other. There was no difference between the side effect rate from albendazole or the double placebo. Praziquantel-treated children had more nausea, abdominal pain, and headache but these side effects were statistically more common in children with schistosomiasis, suggesting a strong influence of dying parasites. The subjects were followed for 6 months for changes in infection status, growth parameters, hemoglobin, and schistosomiasis morbidity. In all 4 sites, a significant 6-month increase in serum hemoglobin was observed in children who received praziquantel, strongly supporting population-based mass treatment.
 ...
PMID:Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. 1006 97

A 29-year-old woman with ovale malaria (most likely contracted, together with asymptomatic schistosomiasis, in East Africa two years previously) had fever, nausea and confusion, jaundice, anaemia, thrombocytopenia, hyponatraemia and hypokalaemia. She was initially diagnosed with and treated for blood-smear-positive vivax malaria. Because of the unusual clinical presentation, blood was analysed by a malaria species-specific nested polymerase chain reaction (PCR) assay which identified Plasmodium ovale as the only infecting species. This case illustrates (i) that a detailed travel history remains a vital part of clinical assessment, (ii) ovale malaria can have an exceptionally long incubation period and features of a moderately severe acute infection, and (iii) PCR assay may prove a valuable adjunct to blood film examination in the diagnosis and speciation of malaria.
 ...
PMID:Parasitic procrastination: late-presenting ovale malaria and schistosomiasis. 1154 81


1 2 Next >>